BoB@BIO: Biotech Investing And Deals With Sofinnova's Maha Radhakrishnan, M.D.
Streams straight from the publisher. podnod never proxies or re-hosts episode audio.
We love to hear from our listeners. Send us a message.
This week's episode of the Business of Biotech was recorded at the BIO Convention in San Diego, where guest Maha Radhakrishnan, M.D., Executive Partner, Private Equity, at Sofinnova, spoke about her move from big pharma and biotech to private equity investing, and what makes a late-stage asset deal work. Maha also talks about how China-originated programs are changing development timelines, and where the next wave of CNS and metabolic innovation could come from.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
We love to hear from our listeners. Send us a message.
buzzsprout.comBusiness of Biotech
lifescienceleader.comBusiness of Biotech newsletter
www9.lifescienceleader.comhttps://www.linkedin.com/in/bencomer/
linkedin.com
- 0:00Live From The BIO Conference
- 1:47Learning Medicine In Russian
- 4:38From Clinical Practice To Pharma Impact
- 7:46Moving From Operator To Investor
- 10:07How Sofinnova Invests In Clinical Stage
- 12:34Late-Stage Asset Value Starts Early
- 18:23China Deals: Speed With Warning Flags
- 24:10New Biotech Operating Models
- 25:41CNS Frontiers Alzheimer’s And Beyond
- 30:44Psychedelics And Next-Gen Psychiatry
- 33:08Multiple Sclerosis Progress And Gaps
- 34:55Next Hot Areas Obesity Muscle DMD
- 38:16Final Takeaways And Where To Subscribe